Veracyte (VCYT) Competitors

Veracyte (NASDAQ:VCYT) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

Do insiders & institutionals hold more shares of VCYT or ADPT?

99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 1.4% of Veracyte shares are owned by company insiders. Comparatively, 6.4% of Adaptive Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Do analysts rate VCYT or ADPT?

Veracyte presently has a consensus target price of $40.90, suggesting a potential upside of 35.34%. Adaptive Biotechnologies has a consensus target price of $12.38, suggesting a potential downside of 5.10%. Given Veracyte's higher probable upside, equities research analysts plainly believe Veracyte is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Adaptive Biotechnologies	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Which has stronger valuation & earnings, VCYT or ADPT?

Veracyte has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$445.76M	5.33	$24.14M	$0.33	91.58
Adaptive Biotechnologies	$178.96M	11.10	-$159.49M	-$0.82	-15.90

Is VCYT or ADPT more profitable?

Veracyte has a net margin of 5.50% compared to Adaptive Biotechnologies' net margin of -59.07%. Veracyte's return on equity of 6.07% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	5.50%	6.07%	5.53%
Adaptive Biotechnologies	-59.07%	-60.93%	-23.03%

Does the media favor VCYT or ADPT?

In the previous week, Adaptive Biotechnologies had 3 more articles in the media than Veracyte. MarketBeat recorded 7 mentions for Adaptive Biotechnologies and 4 mentions for Veracyte. Adaptive Biotechnologies' average media sentiment score of 0.94 beat Veracyte's score of 0.76 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veracyte	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adaptive Biotechnologies	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk & volatility, VCYT or ADPT?

Veracyte has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 1.92, suggesting that its stock price is 92% more volatile than the S&P 500.

Summary

Veracyte beats Adaptive Biotechnologies on 10 of the 16 factors compared between the two stocks.